| http://purl.uniprot.org/citations/34338634 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/34338634 | http://www.w3.org/2000/01/rdf-schema#comment | "Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a series of single-domain antibodies (i.e., nanobody), Nanosota-1, from a camelid nanobody phage display library. Structural data showed that Nanosota-1 bound to the oft-hidden receptor-binding domain (RBD) of SARS-CoV-2 spike protein, blocking viral receptor angiotensin-converting enzyme 2 (ACE2). The lead drug candidate possessing an Fc tag (Nanosota-1C-Fc) bound to SARS-CoV-2 RBD ~3000 times more tightly than ACE2 did and inhibited SARS-CoV-2 pseudovirus ~160 times more efficiently than ACE2 did. Administered at a single dose, Nanosota-1C-Fc demonstrated preventive and therapeutic efficacy against live SARS-CoV-2 infection in both hamster and mouse models. Unlike conventional antibodies, Nanosota-1C-Fc was produced at high yields in bacteria and had exceptional thermostability. Pharmacokinetic analysis of Nanosota-1C-Fc documented an excellent in vivo stability and a high tissue bioavailability. As effective and inexpensive drug candidates, Nanosota-1 may contribute to the battle against COVID-19."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.org/dc/terms/identifier | "doi:10.7554/elife.64815"xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Li F."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Du L."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Perlman S."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Shi K."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Zheng J."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Wan Y."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Ye G."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Aihara H."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Shang J."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Tai W."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Gallant J."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Vickers M."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Odle A."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "Massey C."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/author | "LeBeau A."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/date | "2021"xsd:gYear |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/name | "Elife"xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/pages | "e64815"xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/title | "The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates."xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://purl.uniprot.org/core/volume | "10"xsd:string |
| http://purl.uniprot.org/citations/34338634 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/34338634 |
| http://purl.uniprot.org/citations/34338634 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/34338634 |